GEN vs. SNPS, SNOW, RBLX, ADSK, NET, TEAM, VEEV, TTWO, DDOG, and XYZ
Should you be buying Genesis Healthcare stock or one of its competitors? The main competitors of Genesis Healthcare include Synopsys (SNPS), Snowflake (SNOW), Roblox (RBLX), Autodesk (ADSK), Cloudflare (NET), Atlassian (TEAM), Veeva Systems (VEEV), Take-Two Interactive Software (TTWO), Datadog (DDOG), and Block (XYZ). These companies are all part of the "prepackaged software" industry.
Genesis Healthcare vs. Its Competitors
Synopsys (NASDAQ:SNPS) and Genesis Healthcare (NYSE:GEN) are both large-cap computer and technology companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.
In the previous week, Synopsys had 32 more articles in the media than Genesis Healthcare. MarketBeat recorded 32 mentions for Synopsys and 0 mentions for Genesis Healthcare. Synopsys' average media sentiment score of 1.07 beat Genesis Healthcare's score of 0.00 indicating that Synopsys is being referred to more favorably in the media.
Synopsys currently has a consensus target price of $607.14, indicating a potential upside of 29.03%. Genesis Healthcare has a consensus target price of $33.25, indicating a potential upside of 13.25%. Given Synopsys' stronger consensus rating and higher possible upside, equities analysts plainly believe Synopsys is more favorable than Genesis Healthcare.
Synopsys has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Genesis Healthcare has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.
Synopsys has a net margin of 34.77% compared to Genesis Healthcare's net margin of 17.83%. Genesis Healthcare's return on equity of 155.48% beat Synopsys' return on equity.
85.5% of Synopsys shares are owned by institutional investors. Comparatively, 82.1% of Genesis Healthcare shares are owned by institutional investors. 0.6% of Synopsys shares are owned by company insiders. Comparatively, 3.3% of Genesis Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Synopsys has higher revenue and earnings than Genesis Healthcare. Genesis Healthcare is trading at a lower price-to-earnings ratio than Synopsys, indicating that it is currently the more affordable of the two stocks.
Synopsys received 371 more outperform votes than Genesis Healthcare when rated by MarketBeat users. Likewise, 72.62% of users gave Synopsys an outperform vote while only 65.43% of users gave Genesis Healthcare an outperform vote.
Summary
Synopsys beats Genesis Healthcare on 16 of the 18 factors compared between the two stocks.
Get Genesis Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for GEN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genesis Healthcare Competitors List
Related Companies and Tools
This page (NYSE:GEN) was last updated on 6/20/2025 by MarketBeat.com Staff
Buy GEN Stock Free GEN Stock Alerts